Robbert J. van Alphen

652 total citations
18 papers, 273 citations indexed

About

Robbert J. van Alphen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Robbert J. van Alphen has authored 18 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Genetics. Recurrent topics in Robbert J. van Alphen's work include Cancer Treatment and Pharmacology (5 papers), Estrogen and related hormone effects (5 papers) and Prostate Cancer Treatment and Research (5 papers). Robbert J. van Alphen is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Estrogen and related hormone effects (5 papers) and Prostate Cancer Treatment and Research (5 papers). Robbert J. van Alphen collaborates with scholars based in Netherlands, United States and United Kingdom. Robbert J. van Alphen's co-authors include Ron H.J. Mathijssen, Peter de Bruijn, Jaap Verweij, Ron H. N. van Schaik, Agnes Jager, Esther Oomen‐de Hoop, Teun van Gelder, Paul Hamberg, Maja J.A. de Jonge and Laurent Vernillet and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Pharmaceutical Research.

In The Last Decade

Robbert J. van Alphen

17 papers receiving 267 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robbert J. van Alphen Netherlands	10	132	88	84	71	63	18	273
Jacklyn N. Thibert United States	7	137 1.0×	148 1.7×	161 1.9×	60 0.8×	41 0.7×	9	336
Bolot Kalmyrzaev United Kingdom	7	43 0.3×	63 0.7×	148 1.8×	74 1.0×	79 1.3×	10	272
Sushma Thomas United States	9	125 0.9×	66 0.8×	33 0.4×	96 1.4×	25 0.4×	21	278
Yoshiteru Kamiyama Japan	9	88 0.7×	111 1.3×	27 0.3×	120 1.7×	33 0.5×	9	331
Jenny Mao United States	7	77 0.6×	31 0.4×	25 0.3×	121 1.7×	67 1.1×	11	302
Guillaume Margaillan Canada	8	110 0.8×	90 1.0×	58 0.7×	192 2.7×	28 0.4×	10	316
Liuh Ling Goh Singapore	11	36 0.3×	43 0.5×	21 0.3×	80 1.1×	21 0.3×	28	299
Maria Teresa Landi United States	9	241 1.8×	59 0.7×	66 0.8×	293 4.1×	75 1.2×	18	604
Andrew Shaw United States	10	71 0.5×	18 0.2×	23 0.3×	77 1.1×	28 0.4×	21	243
Hijiri Takeuchi Japan	12	96 0.7×	44 0.5×	51 0.6×	184 2.6×	86 1.4×	31	389

Countries citing papers authored by Robbert J. van Alphen

Since Specialization

Citations

This map shows the geographic impact of Robbert J. van Alphen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robbert J. van Alphen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robbert J. van Alphen more than expected).

Fields of papers citing papers by Robbert J. van Alphen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robbert J. van Alphen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robbert J. van Alphen. The network helps show where Robbert J. van Alphen may publish in the future.

Co-authorship network of co-authors of Robbert J. van Alphen

This figure shows the co-authorship network connecting the top 25 collaborators of Robbert J. van Alphen. A scholar is included among the top collaborators of Robbert J. van Alphen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robbert J. van Alphen. Robbert J. van Alphen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Koëter, Tijmen, Felice N. van Erning, Robbert J. van Alphen, et al.. (2025). The role of adjuvant chemotherapy in rectal cancer: A nationwide cohort study from the Netherlands. Colorectal Disease. 27(3). e70054–e70054. 1 indexed citations

Doorn, Leni van, Yorick Sandberg, Robbert J. van Alphen, et al.. (2024). The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study. Clinical Pharmacokinetics. 63(7). 1037–1044. 2 indexed citations

Armstrong, Andrew J., Noel W. Clarke, Antoine Thiery-Vuillemin, et al.. (2022). Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.. Journal of Clinical Oncology. 40(16_suppl). 5050–5050. 2 indexed citations

Mandjes, Ingrid A.M., Erik van Werkhoven, Harm van Tinteren, et al.. (2021). Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). Breast Care. 16(6). 598–606. 6 indexed citations

Matsubara, Nobuaki, Johann S. de Bono, David Olmos, et al.. (2021). Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.. Journal of Clinical Oncology. 39(6_suppl). 27–27. 15 indexed citations

Braal, C. Louwrens, Agnes Jager, Esther Oomen‐de Hoop, et al.. (2021). Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clinical Pharmacokinetics. 61(4). 527–537. 24 indexed citations

Hussaarts, Koen G. A. M., Lisette Binkhorst, Esther Oomen‐de Hoop, et al.. (2019). The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors. Pharmaceutical Research. 37(1). 7–7. 9 indexed citations

Hussaarts, Koen G. A. M., Daan P. Hurkmans, Esther Oomen‐de Hoop, et al.. (2019). Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. Cancers. 11(3). 403–403. 34 indexed citations

Hussaarts, Koen G. A. M., Esther Oomen‐de Hoop, Peter de Bruijn, et al.. (2019). Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug–drug interaction study. British Journal of Clinical Pharmacology. 85(5). 986–992. 8 indexed citations

10.

Hurkmans, Daan P., Esther Oomen‐de Hoop, Robbert J. van Alphen, et al.. (2018). Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.. Journal of Clinical Oncology. 36(15_suppl). 2572–2572.

11.

Wit, Ronald de, Esther Oomen‐de Hoop, Annemieke J.M. Nieuweboer, et al.. (2017). Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel. Oncotarget. 8(63). 106468–106474. 13 indexed citations

12.

Nieuweboer, Annemieke J.M., Anne‐Joy M. de Graan, Paul Hamberg, et al.. (2016). Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study. Clinical Cancer Research. 23(7). 1679–1683. 12 indexed citations

13.

Punt, Cornelis J.A., Lieke H. J. Simkens, Johan van Rooijen, et al.. (2016). Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.. Journal of Clinical Oncology. 34(15_suppl). 3640–3640. 2 indexed citations

14.

Bins, Sander, Annemieke J.M. Nieuweboer, Anne‐Joy M. de Graan, et al.. (2016). A randomized phase II multicenter trial on the effects of budesonide on cabazitaxel-induced diarrhea: CABARESC.. Journal of Clinical Oncology. 34(15_suppl). 5073–5073. 1 indexed citations

15.

Binkhorst, Lisette, Jacqueline S. L. Kloth, Peter de Bruijn, et al.. (2015). Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Research and Treatment. 152(1). 119–128. 30 indexed citations

16.

Binkhorst, Lisette, M. Bannink, Peter de Bruijn, et al.. (2015). Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. Clinical Pharmacokinetics. 55(2). 249–255. 21 indexed citations

17.

Graan, Anne‐Joy M. de, Sebastiaan F. Teunissen, Filip De Vos, et al.. (2011). Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment. Journal of Clinical Oncology. 29(24). 3240–3246. 42 indexed citations

18.

Jonge, Maja J.A. de, Jaap Verweij, Peter de Bruijn, et al.. (2000). Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin. Journal of Clinical Oncology. 18(1). 195–195. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact